Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 10/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695377 | 0.91 | HRH3 (0.54) | HRH3GAACACNA2D1TOP2ASLC2A1 | |
| SCHEMBL9652160 | 0.88 | HRH3 (0.62) | HRH3 | |
| SCHEMBL11751268 | 0.83 | HRH3 (0.57) | HRH3GAASIGMAR1 | |
| SCHEMBL8907631 | 0.83 | HRH3 (0.60) | HRH3GAA | |
| SCHEMBL8912787 | 0.83 | HRH3 (0.60) | HRH3SLC2A1 | |
| SCHEMBL3454269 | 0.81 | CHRM2 (0.43) | HRH3SIGMAR1 | |
| SCHEMBL1695452 | 0.81 | CHRM2 (0.43) | HRH3SIGMAR1 | |
| SCHEMBL3454549 | 0.81 | KCNH2 (0.60) | HRH3GAASLC6A2SIGMAR1 | |
| SCHEMBL5071096 | 0.81 | HRH3 (0.47) | HRH3GAACACNA2D1SLC6A4SLC6A2 | |
| SCHEMBL1695389 | 0.79 | HTR1A (0.47) | HRH3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126066-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | Avidity Biosciences, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4121063-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Avidity Biosciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3898693-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021195469-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021188390-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-3720448-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | Avidity Biosciences, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3691657-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3684376-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | Avidity Biosciences, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020132584-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | AVIDITY BIOSCIENCES, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019113393-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES LLC (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019071028-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES LLC (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019060775-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES LLC (US) | 2019-03-28 | — | — | WO | disclosed |
| EP-2585113-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA Therapeutics (FR) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012163814-A1 | CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA | INSTITUT CURIE (FR) | 2012-12-06 | — | — | WO | disclosed |
| WO-2011161075-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA THERAPEUTICS (FR) | 2011-12-29 | — | — | WO | disclosed |